Emergent Health Corp.
OperatingRetail & Consumer · King Of Prussia, PA
Financials
FY2020–FY2021 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Jan 3, 2023| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Preferred Stockpreferred(as of Dec 31, 2021) | 25,000,000 | — | 8.75% | — |
| Series A Preferred Stockpreferred(as of Nov 10, 2022) | 100 | — | 0% | — |
| Common Stock | 260,851,111 | — | 91.3% | $0.055Nov 2021 |
| Total | 285,851,211 | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- Sharon McNeil, Trustee, HAR Irrevocable Trust8.3M (14.3%) Nov 2021 → 7.8M (2.74%) Nov 2022
- Christine Arenella5.0M (8.57%) Nov 2021 → 4.5M (1.57%) Nov 2022
- Cimarron Capital, Inc.3.3M (5.71%) Nov 2021 → 3.1M (1.08%) Nov 2022
- Estate of Dr. John Cappello900K (0.31%) Nov 2022 → 33 (0%) Jan 2023
- Leonard Tucker, LLC900K (1.54%) Nov 2021 → 3.9M (1.37%) Nov 2022 → 450K (0.16%) Jan 2023
- Lori Teper4.2M (7.14%) Nov 2021 → 3.9M (1.37%) Nov 2022
Principal holders% as the filing states it, Jan 3, 2023
- Eocine Management Advisors, Inc.66.67 Series A Preferred Stock66.7%of Series A Preferred
- Sharon McNeil, Trustee, HAR Irrevocable Trust7,833,332 Series B Preferred Stock33.3%of Series B Preferred
- Estate of Dr. John Cappello33.33 Series A Preferred Stock33.3%of Series A Preferred
- Regen Biowellness1,500,000 Series C Preferred Stock26.8%of Series C Preferred
- Christine Arenella4,500,000 Series B Preferred Stock19.1%of Series B Preferred
- Lori Teper3,916,667 Series B Preferred Stock16.7%of Series B Preferred
- Estate of Dr. John Cappello900,000 Series C Preferred Stock16.1%of Series C Preferred
- Emerging Capital Advisors, Inc.750,000 Series C Preferred Stock13.4%of Series C Preferred
- James Morrison750,000 Series C Preferred Stock13.4%of Series C Preferred
- Cimarron Capital, Inc.3,083,334 Series B Preferred Stock13.1%of Series B Preferred
- Parcae Capital Corp.450,000 Series C Preferred Stock8.04%of Series C Preferred
- Leonard Tucker, LLC450,000 Series C Preferred Stock8.04%of Series C Preferred
- Cimarron Capital, Inc.300,000 Series C Preferred Stock5.36%of Series C Preferred
- Emerging Capital Structures, Inc.225,000 Series C Preferred Stock4.02%of Series C Preferred
- Adam Brooks225,000 Series C Preferred Stock4.02%of Series C Preferred
- Marvin Segel10,000,000 Common Stock3.83%of company
- Corain McGinn5,000,000 Common Stock1.92%of company
- Christine Arenella50,000 Series C Preferred Stock—of Series C Preferred
Sold to the crowd
- Reg A+ · Nov 202121,645,455 Common Stcok at $0.055$1.2M
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
3 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 17 filings on EDGAR- Form 1-ZJul 20, 20230001903596-23-000548EDGAR
- Form 253G2Feb 7, 20230001903596-23-000110EDGAR
- Form 253G1Jan 12, 20230001903596-23-000043EDGAR
- Form QUALIFJan 6, 20239999999994-23-000010EDGAR
- Form 1-A POSJan 3, 20230001903596-23-000006EDGAR
- Form 1-A/ADec 22, 20220001903596-22-000943EDGAR
- Form 253G1Nov 23, 20220001903596-22-000858EDGAR
- Form QUALIFNov 21, 20229999999994-22-000451EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.